FDA Approves MannKind's Furoscix ReadyFlow Auto-Injector for Heart Failure Edema
MNKD sits 78% above its 52-week low of $2.23.
Summary
The FDA approved MannKind's Furoscix ReadyFlow, the first autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease. This is a major regulatory win that opens a new product category for the company. The device is expected to launch in the U.S. by end of August 2026, providing a near-term commercial catalyst. The approval follows a series of positive regulatory developments, including the FDA's release from the Afrezza postmarketing study and pediatric approval in May-June. With a market cap of $1.2B and a recent net loss, this new product could significantly boost revenues and shift sentiment.
At the time of this announcement, MNKD was trading at $3.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.